LADOCK Software License
Copyright (c) 2024-2026 La Ode Aman
All rights reserved.

Registered with the Directorate General of Intellectual Property (DJKI),
Ministry of Law, Republic of Indonesia:

  Surat Pencatatan Ciptaan No. 001413018
  Application EC002026141582, 13 August 2026
  Title      LADOCK - Molecular Docking Workstation
  Type       Computer Program
  Author and rights holder: Dr. La Ode Aman, M.Si
  First published 27 June 2026; protected for 50 years from that date.

================================================================================
ACADEMIC FREE LICENSE (Limited Period: 2024 – 2029)
================================================================================

During the period of January 1, 2024 through December 31, 2029, LADOCK
is made available FREE OF CHARGE to EVERYONE for non-commercial use, under
the following conditions:

ELIGIBILITY
  The free license is open to all users — students, academics, independent
  researchers, and the general public. No institutional affiliation, verified
  email, registration, or license key is required. The only condition is:
  - Your use of LADOCK is solely for non-commercial purposes (research,
    study, teaching, evaluation, or personal/educational use).

FREE LICENSE TERMS
  - You may install and use LADOCK on any machine for non-commercial work.
  - You may share LADOCK with colleagues for non-commercial use.
  - You must cite the relevant LADOCK publications in any work that uses
    LADOCK (see CITATION section below).
  - You may NOT use LADOCK for any commercial purpose under this license.
  - You may NOT sublicense, sell, or redistribute LADOCK.

AFTER DECEMBER 31, 2029
  The free license period ends. Academic and non-commercial users will be
  eligible for a discounted institutional license. Contact the licensor for
  current academic pricing and renewal terms.

================================================================================
COMMERCIAL LICENSE
================================================================================

Any use of LADOCK by a for-profit company, contract research
organization (CRO), pharmaceutical company, biotechnology firm, or any entity
using LADOCK for commercial purposes requires a COMMERCIAL LICENSE, regardless
of the date.

Commercial use includes but is not limited to:
  - Drug discovery or lead optimization for commercial products
  - Providing docking services to paying clients
  - Integrating LADOCK into a commercial software product or pipeline
  - Internal R&D within a for-profit organization

To obtain a commercial license, contact:
  La Ode Aman
  Email: laode_aman@ung.ac.id
  Subject: LADOCK Commercial License Inquiry

================================================================================
GENERAL TERMS (ALL USERS)
================================================================================

1. OWNERSHIP
   LADOCK, including all source code, binaries, documentation, and
   associated materials, is and remains the exclusive intellectual property
   of La Ode Aman.

2. NO WARRANTY
   LADOCK IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
   IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
   FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT. IN NO EVENT SHALL
   THE AUTHOR BE LIABLE FOR ANY CLAIM, DAMAGES, OR OTHER LIABILITY ARISING
   FROM THE USE OF THIS SOFTWARE.

3. ATTRIBUTION
   All users must retain this copyright notice and license text in any copy
   or substantial portion of the software.

4. TERMINATION
   This license terminates automatically if you violate any of its terms.
   Upon termination, you must cease all use and destroy all copies of LADOCK.

================================================================================
CITATION
================================================================================

If you use LADOCK in your research, please cite:

  Aman LO, Ischak NI, Tuloli TS, Arfan A, Asnawi A. (2024). Multiple ligands
  simultaneous molecular docking and dynamics approach to study the synergetic
  inhibitory of curcumin analogs on ErbB4 tyrosine phosphorylation.
  Research in Pharmaceutical Sciences, 19(6), 754–765.
  https://doi.org/10.4103/RPS.RPS_191_23

================================================================================
CONTACT
================================================================================

  La Ode Aman
  Email: laode_aman@ung.ac.id

  The free non-commercial license needs no verification. For commercial
  licensing inquiries or academic discount pricing (post-2029), please
  contact via email with subject: "LADOCK License Inquiry"